Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Mohamed H Hassan-Ahmed
 -- 3057 2023-10-13 11:34:34 |
2 format
Jason Zhu
 Meta information modification 3057 2023-10-17 03:33:16 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Ahmed, M.H.; Ahmed, F.; Abu-Median, A.; Panourgia, M.; Owles, H.; Ochieng, B.; Ahamed, H.; Wale, J.; Dietsch, B.; Mital, D. Medical Challenges of HIV and Ageing Population. Encyclopedia. Available online: https://encyclopedia.pub/entry/50259 (accessed on 17 May 2024).
Ahmed MH, Ahmed F, Abu-Median A, Panourgia M, Owles H, Ochieng B, et al. Medical Challenges of HIV and Ageing Population. Encyclopedia. Available at: https://encyclopedia.pub/entry/50259. Accessed May 17, 2024.
Ahmed, Mohamed H., Fatima Ahmed, Abu-Bakr Abu-Median, Maria Panourgia, Henry Owles, Bertha Ochieng, Hassan Ahamed, Jane Wale, Benjamin Dietsch, Dushyant Mital. "Medical Challenges of HIV and Ageing Population" Encyclopedia, https://encyclopedia.pub/entry/50259 (accessed May 17, 2024).
Ahmed, M.H., Ahmed, F., Abu-Median, A., Panourgia, M., Owles, H., Ochieng, B., Ahamed, H., Wale, J., Dietsch, B., & Mital, D. (2023, October 13). Medical Challenges of HIV and Ageing Population. In Encyclopedia. https://encyclopedia.pub/entry/50259
Ahmed, Mohamed H., et al. "Medical Challenges of HIV and Ageing Population." Encyclopedia. Web. 13 October, 2023.
Medical Challenges of HIV and Ageing Population
Edit
This entry is adapted from the peer-reviewed paper 10.3390/microorganisms11102426

The continuing increase in patient numbers and improvement in healthcare provisions of HIV services in the UK, alongside the effectiveness of combined antiretroviral therapy (cART), has resulted in increasing numbers of the ageing population among people living with HIV (PLWH). It is expected that geriatricians will need to deal with many older people living with HIV (OPLWH) as life expectancy increases. Therefore, geriatric syndromes in OPLWH will be similar to the normal population, such as falls, cognitive decline, frailty, dementia, hypertension, diabetes and polypharmacy. The increase in the long-term use of cART, diabetes, dyslipidaemia and hypertension may lead to high prevalence of cardiovascular disease (CVD). The treatment of such conditions may lead to polypharmacy and may increase the risk of cART drug–drug interactions. In addition, the risk of developing infection and cancer is high. OPLWH may develop an early onset of low bone mineral density (BMD), osteoporosis and fractures. 

HIV aging psychosocial palliative medicine

1. Introduction

The gradual expansion of HIV services globally and the rapid therapeutic and management advances seen over the last four decades has meant that PLWH are living beyond the age of 50 years, provided that they receive quality-assured monitoring and surveillance of their HIV infection [1][2]. Different types of cART are widely used, with the desired aim of achieving the undetectable HIV-1 viral load seen in most cohorts of PLWH [3]. However, living longer can be associated with observed increases in different medical conditions, as well as cART being associated with different side effects [4][5], and this is reflected in PLWH in both resource-limited and rich countries. This may also be associated with risk of developing neurodegenerative disease, dementia, diabetes, obesity, chronic kidney disease, osteoporosis, frailty, and some cancers [1][6][7][8][9][10]. The risk of fracture also increases in association with osteoporosis and the increased risk of falls [11]. OPLWH are likely to be isolated, and this makes them more prone to mental-health-related illnesses such as anxiety, depression and addiction. This can further cause significant increases in social issues related to stigma, isolation, housing availability and ongoing social support in any one community [12][13].
These age-related issues are expected to increase in OPLWH in the near future. The success of the UNAIDS statement of achieving global 90-90-90 targets (90% aware of their status, 90% on HIV medication, and 90% have viral suppression) has further highlighted the needs of this particular cohort and indeed, a more ambitious 95-95-95 target is hoping to be achieved by 2030. The programme started in 2014 and just eight countries met the targets in 2020. In 2021, the 95-95-95 target was achieved in two countries [2][14][15]. It is estimated that one-fifth of PLWH globally are above the age of 50 years old (around 7.5 million) [2]. Currently, half of total PLWH in the USA are above the age of 50 years old, 15% of PLWH are over 50 years old in sub-Saharan countries and in the Netherlands the number of PLWH aged 50 years is expected to reach 70% by the year 2030 [5].
Despite the improvement in the medical care and treatment of HIV, significant numbers of PLWH die from HIV and HIV-related complications. In systematic reviews and meta-analyses, it was shown that the pooled proportion of patients readmitted to hospital after discharge was 18.8% (95% CI 15.3–22.3) and the percentage who died post-discharge was 14.1% (10.8–17.3). This analysis was conducted in 29 cohorts, including 92,781 PLWH. The study showed that inpatient treatment with cART during hospitalisation was protective against post-discharge mortality. Higher mortalities were seen in Africa (23.1% [16.5–29.7]) than in the USA (7.5% [4.4–10.6]). Importantly, mortality risk factors were associated with a long hospital stay, discharge against medical advice, low CD4 cell counts at admission and lack of follow-up care after discharge [16]. Palliative care is needed to provide symptomatic control such as pain management, anxiety, and nausea, which will further improve wellbeing. Palliative care training also needs to be offered to health professionals caring for OPLWH [17][18].

2. Medical Challenges

HIV can be associated with different and serious medical conditions that can lead to fatal outcomes. The medical conditions will represent extra challenges for geriatricians providing care within the service, which is already overwhelmed with similar conditions in patients without HIV and these are due to the following [19][20][21][22][23][24][25][26][27]:
  • Lack of global plans to establish quality-assured geriatric HIV services.
  • Scarcity of clinical trials available in elderly populations living with HIV.
  • No clinical guidelines are available about the best strategies in the management of medical conditions in elderly populations living with HIV.
  • Issues in relation to geriatricians.
    • Global shortage of trainee and accredited geriatricians.
    • Extreme shortages of geriatricians trained in HIV care and a lack of specific provisions in infectious diseases and related training schemes to provide in-depth knowledge in this area.
    • No clear consensus about a defined age or range a patient will need to see geriatricians, as it can range broadly from the age of 50 or 65 years old.
    • The screening tools used in geriatric medicine are not yet validated in/for HIV populations.
  • Lack of needed guidance for intensive care physicians about who will and will not benefit from admission to intensive care units.
  • Lack of guidance for primary care physicians in the management of medical conditions in elderly populations with HIV.
  • Guidance and consensus are needed for community geriatric service.
  • The need for hospital and community pharmacists to be educated in dealing with drug interactions.
  • Lack of training in HIV care for occupational therapists, physiotherapists and other allied healthcare specialties, e.g., dietitians and podiatrists.
  • Provision of extra funding and capacity building for all the reasons noted above.

2.1. Neurocognitive Disease and Dementia

Alzheimer’s disease (AD) can also be seen in PLWH at middle or older age [28]. The risk of dementia will increase significantly at the age of ≥65 years [29]. The estimated prevalence was suggested to be 2–5% [29][30][31]. HIV-associated dementia (HAD) can be seen in ageing populations living with HIV, whereas HIV-associated neurocognitive disorders were more prevalent in the pre-cART era [32]. However, HIV-associated neurocognitive disorder (HAND) is seen in mild and subtle forms and can be difficult to diagnose. As both conditions can present similarly, both conditions can be classified and managed on best clinical practice, as no definitive treatment is available [33]. In a systematic review and meta-analysis, the prevalence of HAND was estimated to be 50.41%. Factors that can lead to HAND were low level of education, older age, advanced stage of the illness, low CD4 counts of <500 cells/μL and depression [34][35]. Age duration of HIV infection and low CD4 counts appear to represent the main factors leading to HAND [29]. Other factors such as HIV co-infection and other sexually transmitted diseases such as syphilis, hepatitis C and cytomegalovirus can also increase HAND prevalence [36][37]. Other non-communicable diseases that increase risks of HAND development are diabetes, hypertension, obesity and insulin resistance [38][39]. Previous and prolonged depression and apathy can also be contributing factors. The cART, efavirenz was also reported to be associated with cognitive impairment, along with other cARTs such as atzanavir, nevirapine, abacavir and etravirine, whereas less neurotoxicity was noted with tenofovir, darunavir and emtricitabine [40].
Dementia in HIV populations tends to affect fronto-striato-thalamo-cortical circuits. Therefore, in the early stages of HIV infection, individuals may be asymptomatic or develop hyperreflexia. With the progression of HIV and dementia, individuals may develop hypertonia, tremors and clonuses. Features related to Parkinsonism may infrequently develop with slowness in processing information as an important and early diagnostic feature of HAND [41][42]. This can be associated with mental slowness and attention and memory deficits. It is noted that episodic memory impairment with psychomotor slowing can be seen as sensitive indicators in HAND [43].
Regular screening for HAND using validated questionnaires can help in establishing the diagnosis. For instance, The European AIDS society (EACS) recommends regular screening using three questions: (1) Do you have memory loss? (2) Do you feel slowness in planning and solving a problem? and (3) Do you have a problem in paying attention? One positive answer to one of the three questions warrants further investigations. EACS also recommends excluding cofounding factors such as depression, substance abuse or excessive drinking of alcohol [44].
The screening tools used in HAD are the HIV dementia scale (HDS) and international HIV dementia scale (IHDS). The IHDS is easy to utilise and is widely used in different countries, especially where resources are limited. No previous training is required, and it accurately assesses memory, motor speed and psychomotor functions [45]. In a systematic review and meta-analysis, the IHDS showed a sensitivity of 79.4% and a specificity of 65.4% in detecting HAD [46]. The mini-mental state examination (MMSE) and the Montreal cognitive assessment (MoCA) can be used in HAD, but MoCA has more sensitivity and specificity than MMSE [47][48]. The Italian Society for Infectious and Tropical Diseases recommended screening all individuals with HIV for dementia and also recommended using the MoCA [49]. The British HIV Association and the American Association of Infectious Diseases also recommend screening for dementia in the new patients and then once per year [50][51]. No treatment for dementia is yet available, but in HAD the option will be treatment of underlying causes, optimisation of CD4 count through using cART and acetylcholinesterase inhibitors such as memantine [52][53].

2.2. Bone Disease and Osteoporosis

HIV is a condition of chronic inflammation that is associated with a risk of osteoporosis. OPLWH are also at risk of dementia, and this may increase the risk of neglect, falls and bone fractures. The osteoporosis seen in PLWH can potentially begin at the age of 40 or 50 years old [11]. Importantly, HIV per se is an independent risk factor for bone fractures [54]. Hepatitis C virus (HCV) coinfection is associated with a greater risk of osteoporosis and fractures than HIV per se [55]. Some cARTs may also be involved in osteoporosis, such as tenofovir disoproxil fumarate (TDF) [56][57]. Therefore, is not surprising that the risk of fracture increases with HIV. For instance, the fracture risk was found to be 35 to 68% in comparison with the non-HIV-infected population [58][59]. Importantly, the prevalence of vertebral fracture prevalence was found to be 11.1% in PLWH [60]. In clinical practice, the use of the fracture risk assessment tool (FRAX) and measurement of bone mineral density (BMD) via a DEXA scan are widely used in HIV clinics around the world. Bisphosphonates in association with vitamin D and calcium replacement remains the main treatment [61]. Fractures can also be due to increased falls in OPLWH. The cost of living and managing fractures and osteoporosis in older people with HIV can add more burden to the healthcare systems due to the disability and need for special care.

2.3. Falls

HIV is also associated with an increase in the risk of falls. For instance, the prevalence of falls is estimated to be around 12% to 41% [62]. Different studies have shown different related risk factors. Several studies showed an association with decreased physical functions and cognitive impairment [63][64]. OPLWH taking multiple medications can contribute to polypharmacy, which is also regarded as a risk factor for falls. This, in turn, can lead to an increase in co-morbidities that are also potentially linked to peripheral neuropathy [63][64][65][66][67]. Importantly, older age, female and white race were also associated with an increase in falls. The behaviour of the individuals may increase the risk of falls [65][66][67], for instance, substance abuse, having pets and depression are linked with a high risk of falls [63][64][67]. It is plausible that OPLWH have low BMD, which also makes them more at risk of having falls associated with fracture. The high risk of falls and fracture may increase the risk of lowered mobility and disabilities in the future. Therefore, falls and osteoporosis may represent a challenge in the management of PLWH.

2.4. Frailty

Frailty is defined as “an ageing-related syndrome of physiological decline, characterised by marked vulnerability leading to adverse health outcomes” [68]. The symptoms associated with frailty include weakness and fatigue, medical complexities and reduced tolerance to medical and surgical interventions [69]. Frailty is an important issue in geriatric medicine. It is an independent risk factor for the development of cognitive decline [70]. Therefore, the clinicians in all disciplines need to have an awareness of frailty and the associated risks for adverse health outcomes; early identification can improve care for this most vulnerable subset of patients. Frailty is attributed to the fact that ageing causes dysregulation in the normal physiological responses to stressors, resulting in a lack of adaptation and dysfunction of the normal homeostatic responses [71]. Among the risk factors are age, duration of HIV infection >20 years, duration of cART use and smoking [71].
Sarcopenia, which is defined as decreased muscle mass, strength and performance, also shares features of frailty [72]. Sarcopenia prevalence in OPLWH is 24.1% in comparison with 11.1% in individuals without HIV [73]. In a multicentre AIDS cohort study (MACS) bone strength sub-study, the odds of frailty were 4.5 higher in the presence of sarcopenia. It was suggested that there is an interaction between frailty, sarcopenia and functional decline and that sarcopenia can potentiate frailty [74].
Part of the recommendations of the EACS is to screen for frailty once per year for those above 50 years old [75]. There are different tools that can be used to screen for frailty. For instance, The Chelsea and Westminster HIV Clinic in London, UK, published their 10 years of experience in an ageing population with HIV. They used clinical frailty score (CFS) (made up of nine grades, 1 very fit and 9 terminally ill, which is easy to use and widely applied and, most importantly, is a reliable score) and the cut off for referral to a dedicated HIV geriatric service was 5 [76]. HIV is regarded as independent risk factor for frailty; thus, the association of frailty and HIV is associated with high mortality and morbidity [77][78].
The main aim of treatment is the management of disabilities and co-morbidities and all associated geriatric syndromes. For instance, nutrition, exercise and treatment of all reversible causes, including sarcopenia. Frailty is always managed by a multidisciplinary team including geriatricians, HIV physicians, physiotherapists, dietitians, pharmacists, psychologists, social care providers and an occupational therapist if possible [71].

2.5. Polypharmacy and Therapeutic Challenges

OPLWH on cART are aware that this is lifelong therapy. cART is usually given as a combination of different medications and, therefore, it is important for healthcare providers to be familiar with the side effects due to prolonged use. In addition, attention should be given to drug interactions and the risk of polypharmacy [79]. In the UK, the Liverpool HIV drug interactions checker (https://www.hiv-druginteractions.org/checker, accessed on 11 June 2023) is widely used in HIV clinics to assess the safety of other medications beside cART [80]. For instance, simvastatin is not recommended with cART, whereas statins that are not metabolised through the liver (e.g., rosuvastatin) may represent an alternative choice. Examples of the side effects of cART include older protease inhibitors that may cause hypertriglyceridemia, whereas the use of TDF is associated with risk of developing osteopenia and osteoporosis.
Overall, there is an inadequate representation of the older population living without HIV in related clinical trials. This represents a challenge for dedicated healthcare providers, as the pharmacodynamics and pharmacokinetics of medication may change in frail older populations and may cause unnecessary side effects. On some occasions, useful medications may not be given due to unpredictable side effects [81]. The same situations can also be applied to OPLWH; thus, it is imperative that careful revision of all medication should be carried out annually, especially for those >50 years old.

2.6. Infections

HIV in an ageing population can have a serious impact on susceptibility to viral, bacterial and fungal infections. Ageing without HIV is a known risk factor for low immunity, and HIV per se is well known as a disease of the suppression of immunity. Therefore, in the ageing population living with HIV, infection is one of the serious causes of increases in mortality and morbidity. OPLWH may catch different infections such as tuberculosis, hepatitis, sexually transmitted diseases or other viral infections. In the UK, both The British HIV Association (BHIVA) and National Institute for Health and Care Excellence (NICE) advocate screening for latent TB infection (LTBI) and treating it, especially in high-risk individuals [82][83][84][85]. Hepatitis, in general, is one of the major causes of mortality and morbidity in HIV (risk of liver cirrhosis and liver cancer). Hepatitis A, B or C can cause severe and long-lasting liver disease in PLWH, and vaccination is recommended (no sufficient evidence of benefit) [86][87][88][89][90][91][92]. Cytomegalovirus (CMV) has been suggested as a co-factor for the rapid progression of HIV-1 disease, as well as inflammatory and immune response activation. End-organ CMV disease develops in high-risk HIV patients who present with common symptoms such as retinitis but can also involve multiple organs [93][94][95][96].
During the COVID-19 pandemic, older age accompanied by chronic comorbidities was associated with severe outcomes in patients with HIV. Other factors included an absence of ART, low CD4 count and unsuppressed HIV load. There was no increased risk of COVID-19 critical care (ICU and intubation) in patients older than 50 years compared with younger age groups. The risk of death in OPLWH due to COVID-19 potentially increases with co-infection with tuberculosis [97][98][99][100][101]. Other infections reported, such as sexually transmitted diseases, varicella zoster virus, pneumonia, urinary tract infections, fungal infections and parasitic infections [102][103][104][105][106][107][108][109][110][111][112][113][114][115][116][117][118][119][120][121][122][123][124]. Further studies are needed to assess the prevalence of these infections in OPLWH.

2.7. Hypertension, Diabetes, Dyslipidaemia and Cardiovascular Disease

The risk of developing diabetes, hypertension, dyslipidaemia and cardiovascular disease increases with the duration of HIV and cART administration [1][6][8][9]. Unfortunately, the treatment of these conditions can lead to polypharmacy and significantly increase the risk of falls and fracture. Prolonged or regular hypoglycaemia may also enhance the risk of cognitive decline and increase the risk of cardiovascular disease. Diabetes per se can be associated with significant complications such as neuropathy, retinopathy, nephropathy and an elevated risk of developing cardiovascular disease [1][6][8][9]. Therefore, an HIV metabolic clinic is an integral part of HIV services. HIV metabolic clinic in Milton Keynes University Hospital showed promising outcomes in optimising parameters for the management of diabetes, dyslipidaemia and obesity [7]. Choosing the best cART in OPLWH is another medical challenge. The main aim will be to reduce side effects and have an adequate suppression of the viral load. Therefore, most global HIV-1 treatment guidelines suggest giving integrase strand transfer inhibitors (INSTIs) (such as bictegravir or dolutegravir) as a first-line treatment due to the reduced renal, bone and cardiac toxicities; this reduced toxicity is particularly important in an ageing patient. The nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) also have a greater number of metabolic side effects, e.g., more effect on lipids and glucose compared with INSTIs aids this decision-making process (usually in the form of an MDT), with the latter also having a lower pill burden and fewer drug–drug interactions with other medicines, thus being particularly invaluable for polypharmacy issues [9].

References

  1. Husain, N.E.; Ahmed, M.H.; Almobarak, A.O.; Noor, S.K.; Elmadhoun, W.M.; Awadalla, H.; Woodward, C.L.; Mital, D. HIV-Associated Nephropathy in Africa: Pathology, Clinical Presentation and Strategy for Prevention. J. Clin. Med. Res. 2018, 10, 1–8.
  2. Frescura, L.; Godfrey-Faussett, P.; Feizzadeh, A.A.; El-Sadr, W.; Syarif, O.; Ghys, P.D.; on and behalf of the 2025 testing treatment target Working Group. Achieving the 95 95 95 targets for all: A pathway to ending AIDS. PLoS ONE 2022, 17, e0272405.
  3. Edwards, J.K.; Cole, S.R.; Breger, T.L.; Filiatreau, L.M.; Zalla, L.; Mulholland, G.E.; Horberg, M.A.; Silverberg, M.J.; Gill, M.J.; Rebeiro, P.F.; et al. Five-Year Mortality for Adults Entering Human Immunodeficiency Virus Care Under Universal Early Treatment Compared with the General US Population. Clin. Infect. Dis. 2022, 75, 867–874.
  4. Autenrieth, C.S.; Beck, E.J.; Stelzle, D.; Mallouris, C.; Mahy, M.; Ghys, P. Global and regional trends of people living with HIV aged 50 and over: Estimates and projections for 2000–2020. PLoS ONE 2018, 13, e0207005.
  5. Smit, M.; Brinkman, K.; Geerlings, S.; Smit, C.; Thyagarajan, K.; van Sighem, A.; de Wolf, F.; Hallett, T.B. Future challenges for clinical care of an ageing population infected with HIV: A modelling study. Lancet Infect. Dis. 2015, 15, 810–818.
  6. Ahmed, M.H.; Husain, N.E.; Malik, A.; Woodward, C.; Mital, D. Non-Alcoholic Fatty Liver Disease and HIV/AIDS: A New Way of Modulation of Cardiovascular Risk. AIDS Rev. 2017, 19, 190–197.
  7. Ahmed, M.H.; Woodward, C.; Mital, D. Metabolic clinic for individuals with HIV/AIDS: A commitment and vision to the future of HIV services. Cardiovasc. Endocrinol. 2017, 6, 109–112.
  8. Youssef, J.; Sadera, R.; Mital, D.; Ahmed, M.H. HIV and the Pituitary Gland: Clinical and Biochemical Presentations. J. Lab. Physicians 2021, 13, 84–90.
  9. Ahmed, M.; Ahmed, M.; Mital, D.; Ahmed, M.H. Management of hypercholesterolemia in individuals living with HIV/AIDS. In Cholesterol: From Chemistry and Biophysics to the Clinic; Academic Press: Cambridge, MA, USA, 2022; pp. 999–1020.
  10. Frey, E.; Johnston, C.D.; Siegler, E.L. Treatment Regimens and Care Models for Older Patients Living with HIV: Are We Doing Enough? HIV AIDS 2023, 15, 191–208.
  11. Ahmed, M.; Mital, D.; Abubaker, N.E.; Panourgia, M.; Owles, H.; Papadaki, I.; Ahmed, M.H. Bone Health in People Living with HIV/AIDS: An Update of Where We Are and Potential Future Strategies. Microorganisms 2023, 11, 789.
  12. Chichetto, N.E.; Kundu, S.; Freiberg, M.S.; Koethe, J.R.; Butt, A.A.; Crystal, S.; So-Armah, K.A.; Cook, R.L.; Braithwaite, R.S.; Justice, A.C.; et al. Association of Syndemic Unhealthy Alcohol Use, Smoking, and Depressive Symptoms on Incident Cardiovascular Disease among Veterans with and without HIV-Infection. AIDS Behav. 2021, 25, 2852–2862.
  13. Caniglia, E.C.; Khan, M.; Ban, K.; Braithwaite, R.S. Integrating Screening and Treatment of Unhealthy Alcohol Use and Depression with Screening and Treatment of Anxiety, Pain, and Other Substance Use among People with HIV and Other High-Risk Persons. AIDS Behav. 2021, 25 (Suppl. 3), 339–346.
  14. Farley, S.M.; Wang, C.; Bray, R.M.; Low, A.J.; Delgado, S.; Hoos, D.; Kakishozi, A.N.; Harris, T.G.; Nyirenda, R.; Wadonda, N.; et al. Progress towards the UNAIDS 90-90-90 targets among persons aged 50 and older living with HIV in 13 African countries. J. Int. AIDS Soc. 2022, 25 (Suppl. 4), e26005.
  15. Chipanta, D.; Amo-Agyei, S.; Giovenco, D.; Estill, J.; Keiser, O. Socioeconomic inequalities in the 90–90–90 target, among people living with HIV in 12 sub-Saharan African countries—Implications for achieving the 95–95–95 target—Analysis of population-based surveys. eClinicalMedicine 2022, 53, 101652.
  16. Ford, N.; Patten, G.; Rangaraj, A.; Davies, M.-A.; Meintjes, G.; Ellman, T. Outcomes of people living with HIV after hospital discharge: A systematic review and meta-analysis. Lancet HIV 2022, 9, e150–e159.
  17. Rangaraj, A.; Connor, S.; Harding, R.; Pinto, C.; Chitembo, L.; Ford, N. Advanced HIV disease and health-related suffering—Exploring the unmet need of palliative care. Lancet HIV 2023, 10, e126–e133.
  18. Harding, R. Palliative care as an essential component of the HIV care continuum. Lancet HIV 2018, 5, e524–e530.
  19. Marty, L.; Diawara, Y.; Rachas, A.; Grabar, S.; Costagliola, D.; Supervie, V. Projection of age of individuals living with HIV and time since ART initiation in 2030: Estimates for France. J. Int. AIDS Soc. 2022, 25, e25986.
  20. Dotchin, C.L.; Akinyemi, R.O.; Gray, W.K.; Walker, R.W. Geriatric medicine: Services and training in Africa. Age Ageing 2013, 42, 124–128.
  21. Pati, S.; Sharma, A.; Pati, S.; Zodpey, S. Teaching of geriatric health in India: Mapping the terrain. Gerontol. Geriatr. Educ. 2017, 38, 92–103.
  22. Guaraldi, G.; Rockwood, K. Geriatric-HIV Medicine Is Born. Clin. Infect. Dis. 2017, 65, 507–509.
  23. AGS. Guiding Principles for the Care of Older Adults with Multimorbidity: An Approach for Clinicians: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. J. Am. Geriatr. Soc. 2012, 60, E1–E25.
  24. Singh, H.K.; Del Carmen, T.; Freeman, R.; Glesby, M.J.; Siegler, E.L. From One Syndrome to Many: Incorporating Geriatric Consultation Into HIV Care. Clin. Infect. Dis. 2017, 65, 501–506.
  25. Siegler, E.L.; Burchett, C.O.; Glesby, M.J. Older people with HIV are an essential part of the continuum of HIV care. J. Int. AIDS Soc. 2018, 21, e25188.
  26. Lorenz, D.R.; Mukerji, S.S.; Misra, V.; Uno, H.; Gelman, B.B.; Moore, D.J.; Singer, E.J.; Morgello, S.; Gabuzda, D. Multimorbidity networks associated with frailty among middle-aged and older people with HIV. AIDS 2021, 35, 2451–2461.
  27. Turin, C.G.; Khanjee, N.; Breaux, K.; Armamento-Villareal, R.; Rodriguez-Barradas, M.C.; Clark, E.H. Evaluation of Adherence to Guideline-Based Bone Mineral Density Screening in Veterans with HIV. AIDS Res. Hum. Retroviruses 2022, 38, 216–221.
  28. Sundermann, E.E.; Campbell, L.M.; Villers, O.; Bondi, M.W.; Gouaux, B.; Salmon, D.P.; Galasko, D.; Soontornniyomkij, V.; Ellis, R.J.; Moore, D.J. Alzheimer’s Disease Pathology in Middle Aged and Older People with HIV: Comparisons with Non-HIV Controls on a Healthy Aging and Alzheimer’s Disease Trajectory and Relationships with Cognitive Function. Viruses 2023, 15, 1319.
  29. Wei, J.; Hou, J.; Su, B.; Jiang, T.; Guo, C.; Wang, W.; Zhang, Y.; Chang, B.; Wu, H.; Zhang, T. The Prevalence of Frascati-Criteria-Based HIV-Associated Neurocognitive Disorder (HAND) in HIV-Infected Adults: A Systematic Review and Meta-Analysis. Front. Neurol. 2020, 11, 581346.
  30. Mekuriaw, B.; Belayneh, Z.; Teshome, W.; Akalu, Y. Prevalence and variability of HIV/AIDS-associated neurocognitive impairments in Africa: A systematic review and meta-analysis. BMC Public Health 2023, 23, 997.
  31. Wang, Y.; Liu, M.; Lu, Q.; Farrell, M.; Lappin, J.; Shi, J.; Lu, L.; Bao, Y. Global prevalence and burden of HIV-associated neurocognitive disorder: A meta-analysis. Neurology 2020, 95, e2610–e2621.
  32. Vastag, Z.; Fira-Mladinescu, O.; Rosca, E.C. HIV-Associated Neurocognitive Disorder (HAND): Obstacles to Early Neuro-psychological Diagnosis. Int. J. Gen. Med. 2022, 15, 4079–4090.
  33. Cornea, A.; Lata, I.; Simu, M.; Rosca, E.C. Assessment and Diagnosis of HIV-Associated Dementia. Viruses 2023, 15, 378.
  34. Zenebe, Y.; Necho, M.; Yimam, W.; Akele, B. Worldwide Occurrence of HIV-Associated Neurocognitive Disorders and Its Associated Factors: A Systematic Review and Meta-Analysis. Front. Psychiatry 2022, 13, 814362.
  35. Zenebe, Y.; Akele, B.; W/Selassie, M.; Necho, M. A systematic review and meta-analysis of HIV associated neurocognitive disorders (HAND) among people with HIV in Ethiopia. AIDS Res. Ther. 2021, 18, 99.
  36. Vance, D.E.; Randazza, J.; Fogger, S.; Slater, L.Z.; Humphrey, S.C.; Keltner, N.L. An overview of the biological and psychosocial context surrounding neurocognition in HIV. J. Am. Psychiatr. Nurses Assoc. 2014, 20, 117–124.
  37. Wallace, M.R.; Heaton, R.K.; McCutchan, J.A.; Malone, J.L.; Velin, R.; Nelson, J.; Miller, L.K.; Weiss, P.J.; Oldfield, E.C., 3rd; Grant, I. Neurocognitive impairment in human immunodeficiency virus infection is correlated with sexually transmitted dis-ease history. Sex. Transm. Dis. 1997, 24, 398–401.
  38. Wright, E.J.; Grund, B.; Robertson, K.; Brew, B.J.; Roediger, M.; Bain, M.P.; Drummond, F.; Vjecha, M.J.; Hoy, J.; Miller, C.; et al. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 2010, 75, 864–873.
  39. Fabbiani, M.; Ciccarelli, N.; Tana, M.; Farina, S.; Baldonero, E.; Di Cristo, V.; Colafigli, M.; Tamburrini, E.; Cauda, R.; Silveri, M.; et al. Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients. HIV Med. 2013, 14, 136–144.
  40. Robertson, K.; Liner, J.; Meeker, R.B. Antiretroviral neurotoxicity. J. Neurovirol. 2012, 18, 388–399.
  41. Valcour, V.; Watters, M.R.; Williams, A.E.; Sacktor, N.; McMurtray, A.; Shikuma, C. Aging exacerbates extrapyramidal motor signs in the era of highly active antiretroviral therapy. J. Neurovirol. 2008, 14, 362–367.
  42. Sankhla, C.; Soman, R.; Gupta, N.; Shah, P. Movement disorder: A manifestation of HIV and its response to therapy. Neurol. India 2009, 57, 789–791.
  43. Woods, S.P.; Moore, D.J.; Weber, E.; Grant, I. Cognitive Neuropsychology of HIV-Associated Neurocognitive Disorders. Neuropsychol. Rev. 2009, 19, 152–168.
  44. EACS. European AIDS Clinical Society Guidelines. Available online: https://www.eacsociety.org/media/guidelines-11.1_final_09-10.pdf (accessed on 3 August 2023).
  45. Antinori, A.; Arendt, G.; Grant, I.; Letendre, S.; Chair; Munoz-Moreno, J.A.; Eggers, C.; Brew, B.; Brouillette, M.J.; Bernal-Cano, F.; et al. Assessment, Diagnosis, and Treatment of HIV-Associated Neurocognitive Disorder: A Consensus Report of the Mind Exchange Program. Clin. Infect. Dis. 2013, 56, 1004–1017.
  46. Rosca, E.C.; Tadger, P.; Cornea, A.; Tudor, R.; Oancea, C.; Simu, M. International HIV Dementia Scale for HIV-Associated Neurocognitive Disorders: A Systematic Review and Meta-Analysis. Diagnostics 2021, 11, 1124.
  47. Milanini, B.; Ciccarelli, N.; Fabbiani, M.; Baldonero, E.; Limiti, S.; Gagliardini, R.; Borghetti, A.; D’Avino, A.; Mondi, A.; Colafigli, M.; et al. Neuropsychological screening tools in Italian HIV+ patients: A comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE). Clin. Neuropsychol. 2016, 30, 1457–1468.
  48. Zipursky, A.R.; Gogolishvili, D.; Rueda, S.; Brunetta, J.; Carvalhal, A.; McCombe, J.A.; Gill, M.J.; Rachlis, A.; Rosenes, R.; Arbess, G.; et al. Evaluation of brief screening tools for neurocognitive impairment in HIV/AIDS: A systematic review of the literature. Aids 2013, 27, 2385–2401.
  49. New Italian Guidelines on the Use of Antiretroviral Therapy and the Clinical-Diagnostic Management of HIV-1 Affected Patients. Available online: https://penta-id.org/news/new-italian-guidelines-on-the-use-of-antiretroviral-therapy-and-the-clinicaldiagnostic-management-of-hiv-1-affected-patients/ (accessed on 2 August 2023).
  50. British HIV Association. BHIVA Guidelines for the Routine Investigation and Monitoring of Adult HIV-1-Positive Individuals2016 (2019 Interim Update). Available online: https://www.bhiva.org/monitoring-guidelines (accessed on 11 June 2023).
  51. Thompson, M.A.; Horberg, M.A.; Agwu, A.L.; Colasanti, J.A.; Jain, M.K.; Short, W.R.; Singh, T.; A Aberg, J. Primary Care Guidance for Persons with Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin. Infect. Dis. 2020, 73, e3572–e3605.
  52. Eggers, C.; Arendt, G.; Hahn, K.; Husstedt, I.W.; Maschke, M.; Neuen-Jacob, E.; Obermann, M.; Rosenkranz, T.; Schielke, E.; Straube, E. HIV-1-associated neurocognitive disorder: Epidemiology, pathogenesis, diagnosis, and treatment. J. Neurol. 2017, 264, 1715–1727.
  53. Winston, A.; Spudich, S. Cognitive disorders in people living with HIV. Lancet HIV 2020, 7, e504–e513.
  54. Thomsen, M.T.; Wiegandt, Y.L.; Gelpi, M.; Knudsen, A.D.; Fuchs, A.; Sigvardsen, P.E.; Kühl, J.T.; Nordestgaard, B.; Køber, L.; Lundgren, J.; et al. Prevalence of and Risk Factors for Low Bone Mineral Density Assessed by Quantitative Computed To-mography in People Living with HIV and Uninfected Controls. J. Acquir. Immune Defic. Syndr. 2020, 83, 165–172.
  55. Dong, H.V.; Cortes, Y.I.; Shiau, S.; Yin, M.T. Osteoporosis and fractures in HIV/hepatitis C virus coinfection: A systematic review and meta-analysis. AIDS 2014, 28, 2119–2131.
  56. Maggiolo, F.; Rizzardini, G.; Raffi, F.; Pulido, F.; Mateo-Garcia, M.G.; Molina, J.-M.; Ong, E.; Shao, Y.; Piontkowsky, D.; Das, M.; et al. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: A multicentre, open-label, phase 3b, randomised trial. Lancet HIV 2019, 6, e655–e666.
  57. Baranek, B.; Wang, S.; Cheung, A.M.; Mishra, S.; Tan, D.H. The Effect of Tenofovir Disoproxil Fumarate on Bone Mineral Density: A Systematic Review and Meta-Analysis. Antivir. Ther. 2020, 25, 21–32.
  58. Shiau, S.; Broun, E.C.; Arpadi, S.M.; Yin, M.T. Incident fractures in HIV-infected individuals: A systematic review and meta-analysis. AIDS 2013, 27, 1949–1957.
  59. O’neill, T.J.; Rivera, L.; Struchkov, V.; Zaheen, A.; Thein, H.-H. The Effect of HIV-Hepatitis C Co-Infection on Bone Mineral Density and Fracture: A Meta-Analysis. PLoS ONE 2014, 9, e101493.
  60. Ilha, T.A.S.H.; Comim, F.V.; Copes, R.M.; Compston, J.E.; Premaor, M.O. HIV and Vertebral Fractures: A Systematic Review and Metanalysis. Sci. Rep. 2018, 8, 7838.
  61. Starup-Linde, J.; Rosendahl, S.B.; Storgaard, M.; Langdahl, B. Management of Osteoporosis in Patients Living with HIV—A Systematic Review and Meta-analysis. J. Acquir. Immune Defic. Syndr. 2020, 83, 1–8.
  62. Charumbira, M.Y.; Berner, K.; Louw, Q.A. Falls in people living with HIV: A scoping review. BMJ Open 2020, 10, e034872.
  63. Erlandson, K.; Plankey, M.; Springer, G.; Cohen, H.; Cox, C.; Hoffman, H.; Yin, M.; Brown, T. Fall frequency and associated factors among men and women with or at risk for HIV infection. HIV Med. 2016, 17, 740–748.
  64. Erlandson, K.M.; Allshouse, A.A.; Jankowski, C.M.; Duong, S.; MaWhinney, S.S.; Kohrt, W.M.; Campbell, T.B. Risk Factors for Falls in HIV-Infected Persons. J. Acquir. Immune Defic. Syndr. 2012, 61, 484–489.
  65. Erlandson, K.M.; Zhang, L.; Ng, D.K.; Althoff, K.N.; Palella, F.J.J.; Kingsley, L.A.D.; Jacobson, L.P.S.; Margolick, J.B.; Lake, J.E.M.; Brown, T.T. Risk Factors for Falls, Falls with Injury, and Falls with Fracture among Older Men with or at Risk of HIV Infection. J. Acquir. Immune Defic. Syndr. 2019, 81, e117–e126.
  66. Sharma, A.; Hoover, D.R.; Shi, Q.; Holman, S.; Plankey, M.W.; Tien, P.C.; Weber, K.M.; Floris-Moore, M.; Bolivar, H.H.; Vance, D.E.; et al. Longitudinal study of falls among HIV-infected and uninfected women: The role of cognition. Antivir. Ther. 2017, 23, 179–190.
  67. Sharma, A.; Hoover, D.R.; Shi, Q.; Holman, S.; Plankey, M.W.; Wheeler, A.L.; Weber, K.; Floris-Moore, M.; Bolivar, H.H.; Vance, D.E.; et al. Falls among Middle-Aged Women in the Women’s Interagency HIV Study. Antivir. Ther. 2015, 21, 697–706.
  68. Thurn, M.; Gustafson, D.R. Faces of Frailty in Aging with HIV Infection. Curr. HIV/AIDS Rep. 2017, 14, 31–37.
  69. Vermeiren, S.; Vella-Azzopardi, R.; Beckwée, D.; Habbig, A.-K.; Scafoglieri, A.; Jansen, B.; Bautmans, I.; Gerontopole Brussels Study group. Frailty and the Prediction of Negative Health Outcomes: A Meta-Analysis. J. Am. Med. Dir. Assoc. 2016, 17, 1163.e1–1163.e17.
  70. Falutz, J.; Kirkland, S.; Guaraldi, G. Geriatric Syndromes in People Living with HIV Associated with Ageing and Increasing Comorbidities: Implications for Neurocognitive Complications of HIV Infection. Curr. Top. Behav. Neurosci. 2021, 50, 301–327.
  71. Kehler, D.S.; Milic, J.; Guaraldi, G.; Fulop, T.; Falutz, J. Frailty in older people living with HIV: Current status and clinical management. BMC Geriatr. 2022, 22, 919.
  72. Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; et al. Sarcopenia: Revised European consensus on defnition and diagnosis. Age Ageing 2019, 48, 16–31.
  73. Oliveira, V.H.F.; Borsari, A.L.; Webel, A.R.; Erlandson, K.M.; Deminice, R. Sarcopenia in people living with the human immuno-defciency virus: A systematic review and meta-analysis. Eur. J. Clin. Nutr. 2020, 74, 1009–1021.
  74. Hawkins, K.L.; Zhang, L.; Ng, D.K.; Althoff, K.N.; Palella, F.J., Jr.; Kingsley, L.A.; Jacobson, L.P.; Margolick, J.B.; Lake, J.E.; Brown, T.T.; et al. Abdominal obesity, sarcopenia, and osteoporosis are associated with frailty in men living with and without HIV. AIDS 2018, 32, 1257–1266.
  75. Frailty. EACS Guidelines Version 11. 2022. Available online: https://eacs.sanfordguide.com/prevention-non-infectious-co-morbidities/frailty (accessed on 4 August 2023).
  76. Pereira, B.; Mazzitelli, M.; Milinkovic, A.; Casley, C.; Rubio, J.; Channa, R.; Girometti, N.; Asboe, D.; Pozniak, A.; Boffito, M. Evaluation of a Clinic Dedicated to People Aging with HIV at Chelsea and Westminster Hospital: Results of a 10-Year Experience. AIDS Res. Hum. Retroviruses 2022, 38, 188–197.
  77. Brañas, F.; Torralba, M.; Antela, A.; Vergas, J.; Ramírez, M.; Ryan, P.; Dronda, F.; Galindo, M.J.; Machuca, I.; Bustinduy, M.J.; et al. Effects of frailty, geriatric syndromes, and comorbidity on mortality and quality of life in older adults with HIV. BMC Geriatr. 2023, 23, 4.
  78. Kooij, K.W.; Wit, F.W.; Schouten, J.; van der Valk, M.; Godfried, M.H.; Stolte, I.G.; Prins, M.; Falutz, J.; Reiss, P. HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls. AIDS 2016, 30, 241–250.
  79. Back, D.; Marzolini, C. The challenge of HIV treatment in an era of polypharmacy. J. Int. AIDS Soc. 2020, 23, e25449.
  80. Drwiega, E.N.; Badowski, M.E.; Michienzi, S. Antiretroviral drug–drug interactions: A comparison of online drug interaction databases. J. Clin. Pharm. Ther. 2022, 47, 1720–1724.
  81. Freedman, S.F.; Johnston, C.; Faragon, J.J.; Siegler, E.L.; Del Carmen, T. Older HIV-infected adults: Complex patients (III)—Polypharmacy. Eur. Geriatr. Med. 2018, 10, 199–211.
  82. White, H.A.; Miller, R.F.; Pozniak, A.L.; Lipman, M.C.I.; Stephenson, I.; Wiselka, M.J.; Pareek, M. Latent tuberculosis infection screening and treatment in HIV: Insights from evaluation of UK practice. Thorax 2016, 72, 180–182.
  83. White, H.A.; Baggaley, R.F.; Okhai, H.; Patel, H.; Stephenson, I.; Bodimeade, C.; Wiselka, M.J.; Pareeka, M. The impact, effectiveness and outcomes of targeted screening thresholds for programmatic latent tuberculosis infection testing in HIV. AIDS 2022, 36, 2035–2044.
  84. Barr, D.A.; Lewis, J.M.; Feasey, N.; Schutz, C.; Kerkhoff, A.D.; Jacob, S.T.; Andrews, B.; Kelly, P.; Lakhi, S.; Muchemwa, L.; et al. Mycobacterium tuberculosis bloodstream infection prevalence, diagnosis, and mortality risk in seriously ill adults with HIV: A systematic review and meta-analysis of individual patient data. Lancet Infect. Dis. 2020, 20, 742–752.
  85. Khan, F.A.; Minion, J.; Al-Motairi, A.; Benedetti, A.; Harries, A.D.; Menzies, D. An Updated Systematic Review and Meta-analysis on the Treatment of Active Tuberculosis in Patients with HIV Infection. Clin. Infect. Dis. 2012, 55, 1154–1163.
  86. Abimbola, T.O.; Van Handel, M.; Tie, Y.; Ouyang, L.; Nelson, N.; Weiser, J. Cost-effectiveness of expanded hepatitis A vaccination among adults with diagnosed HIV, United States. PLoS ONE 2023, 18, e0282972.
  87. Chen, S.; Ren, F.; Huang, X.; Xu, L.; Gao, Y.; Zhang, X.; Cao, Y.; Fan, Z.; Tian, Y.; Liu, M. Underestimated Prevalence of HIV, Hepatitis B Virus (HBV), and Hepatitis D Virus (HDV) Triple Infection Globally: Systematic Review and Meta-analysis. JMIR Public Health Surveill. 2022, 8, e37016.
  88. Fabrizi, F.; Dixit, V.; Martin, P.; Messa, P. Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: Systematic review and meta-analysis. J. Med. Virol. 2016, 88, 487–497.
  89. Ni, J.D.; Xiong, Y.Z.; Wang, X.J.; Xiu, L.C. Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard dose vaccination: A meta-analysis? Int. J. STD AIDS 2013, 24, 117–122.
  90. Lee, J.-H.; Hong, S.; Im, J.H.; Lee, J.-S.; Baek, J.H.; Kwon, H.Y. Systematic review and meta-analysis of immune response of double dose of hepatitis B vaccination in HIV-infected patients. Vaccine 2020, 38, 3995–4000.
  91. Wyatt, C.M.; Malvestutto, C.; Coca, S.G.; Klotman, P.E.; Parikh, C.R. The impact of hepatitis C virus coinfection on HIV-related kidney disease: A systematic review and meta-analysis. AIDS 2008, 22, 1799–1807.
  92. Okwen, M.P.; Reid, S.; Njei, B.; Mbuagbaw, L. Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infection. Cochrane Database Syst. Rev. 2014, 10, CD009886.
  93. Perello, R.; Vergara, A.; Monclus, E.; Jimenez, S.; Montero, M.; Saubi, N.; Moreno, A.; Eto, Y.; Inciarte, A.; Mallolas, J.; et al. Cytomegalovirus infection in HIV-infected patients in the era of combination antiretroviral therapy. BMC Infect. Dis. 2019, 19, 1030.
  94. Lurain, N.S.; Hanson, B.A.; Hotton, A.L.; Weber, K.M.; Cohen, M.H.; Landay, A.L.; Martins, L.J.; Bonczkowski, P.; Spivak, A.M.; De Spiegelaere, W.; et al. The Association of Human Cytomegalovirus with Biomarkers of Inflammation and Immune Activation in HIV-1-Infected Women. AIDS Res. Hum. Retroviruses 2016, 32, 134–143.
  95. Crum, N.F.; Riffenburgh, R.H.; Wegner, S.; Agan, B.K.; Tasker, S.A.; Spooner, K.M.; Armstrong, A.W.; Fraser, S.; Wallace, M.R.; Triservice AIDS Clinical Consortium. Comparisons of causes of death and mortality rates among HIV-infected persons: Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J. Acquir. Immune Defic. Syndr. 2006, 41, 194–200.
  96. Wohl, D.A.; Zeng, D.; Stewart, P.; Glomb, N.; Alcorn, T.; Jones, S.; Handy, J.; Fiscus, S.; Weinberg, A.; Gowda, D.; et al. Cytomegalovirus Viremia, Mortality, and End-Organ Disease among Patients with AIDS Receiving Potent Antiretroviral Therapies. Am. J. Ther. 2005, 38, 538–544.
  97. Hanna, J.J.; Geresu, L.B.; Diaz, M.I.; Ho, M.; Casazza, J.A.; Pickering, M.A.; Lanier, H.D.; Radunsky, A.P.; Cooper, L.N.; Saleh, S.N.; et al. Risk Factors for SARS-CoV-2 Infection and Severe Outcomes among People with Human Immunodeficiency Virus: Cohort Study. Open Forum Infect. Dis. 2023, 10, ofad400.
  98. Bertagnolio, S.; Thwin, S.S.; Silva, R.; Nagarajan, S.; Jassat, W.; Fowler, R.; Haniffa, R.; Reveiz, L.; Ford, N.; Doherty, M.; et al. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: Analysis of data from the WHO Global Clinical Platform of COVID-19. Lancet HIV 2022, 9, e486–e495.
  99. Inciarte, A.; Gonzalez-Cordon, A.; Rojas, J.; Torres, B.; de Lazzari, E.; de la Mora, L.; Martinez-Rebollar, M.; Laguno, M.; Callau, P.; Gonzalez-Navarro, A.; et al. Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: A single-center, prospective observational study. AIDS 2020, 34, 1775–1780.
  100. Western Cape Department of Health in Collaboration with the National Institute for Communicable Diseases, South Africa. Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. Clin. Infect. Dis. 2021, 73, e2005–e2015, Erratum in: Clin. Infect. Dis. 2022, 74, 1321.
  101. Ssentongo, P.; Heilbrunn, E.S.; Ssentongo, A.E.; Advani, S.; Chinchilli, V.M.; Nunez, J.J.; Du, P. Epidemiology and outcomes of COVID-19 in HIV-infected individuals: A systematic review and meta-analysis. Sci. Rep. 2021, 11, 6283.
  102. Rodríguez, A.C.; Schiffman, M.; Herrero, R.; Hildesheim, A.; Bratti, C.; Sherman, M.E.; Solomon, D.; Guillén, D.; Alfaro, M.; Morales, J.; et al. Longitudinal Study of Human Papillomavirus Persistence and Cervical Intraepithelial Neoplasia Grade 2/3: Critical Role of Duration of Infection. J. Natl. Cancer Inst. 2010, 102, 315–324.
  103. Frisch, M.; Biggar, R.J.; Goedert, J.J. Human Papillomavirus-Associated Cancers in Patients with Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome. J. Natl. Cancer Inst. 2000, 92, 1500–1510.
  104. Pauk, J.; Huang, M.-L.; Brodie, S.J.; Wald, A.; Koelle, D.M.; Schacker, T.; Celum, C.; Selke, S.; Corey, L. Mucosal Shedding of Human Herpesvirus 8 in Men. N. Engl. J. Med. 2000, 343, 1369–1377.
  105. Colón-López, V.; Shiels, M.S.; Machin, M.; Ortiz, A.P.; Strickler, H.; Castle, P.E.; Pfeiffer, R.M.; Engels, E.A. Anal Cancer Risk among People with HIV Infection in the United States. J. Clin. Oncol. 2018, 36, 68–75.
  106. Rohner, E.; Wyss, N.; Heg, Z.; Faralli, Z.; Mbulaiteye, S.M.; Novak, U.; Zwahlen, M.; Egger, M.; Bohlius, J. HIV and human herpesvirus 8 co-infection across the globe: Systematic review and meta-analysis. Int. J. Cancer 2015, 138, 45–54.
  107. Bunge, E.M.; Hoet, B.; Chen, L.; Lienert, F.; Weidenthaler, H.; Baer, L.R.; Steffen, R. The changing epidemiology of human monkeypox—A potential threat? A systematic review. PLoS Neglected Trop. Dis. 2022, 16, e0010141.
  108. Adachi, K.; Klausner, J.D.; Bristow, C.C.; Xu, J.; Ank, B.; Morgado, M.G.; Watts, D.H.; Weir, F.; Persing, D.; Mofenson, L.M.; et al. Chlamydia and Gonorrhea in HIV-Infected Pregnant Women and Infant HIV Transmission. Sex. Transm. Dis. 2015, 42, 554–565.
  109. Gebo, A.K.; Kalyani, R.; Moore, R.D.; Polydefkis, M.J. The Incidence of, Risk Factors for, and Sequelae of Herpes Zoster among HIV Patients in the Highly Active Antiretroviral Therapy Era. J. Acquir. Immune Defic. Syndr. 2005, 40, 169–174.
  110. Grabar, S.; Tattevin, P.; Selinger-Leneman, H.; de La Blanchardiere, A.; de Truchis, P.; Rabaud, C.; Rey, D.; Daneluzzi, V.; Ferret, S.; Lascaux, A.-S.; et al. Incidence of Herpes Zoster in HIV-Infected Adults in the Combined Antiretroviral Therapy Era: Results From the FHDH-ANRS CO4 Cohort. Clin. Infect. Dis. 2015, 60, 1269–1277.
  111. Domingo, P.; Torres, O.H.; Ris, J.; Vazquez, G. Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection. Am. J. Med. 2001, 110, 605–609.
  112. Head, B.M.; Mao, R.; Keynan, Y.; Rueda, Z.V. Inflammatory mediators and lung abnormalities in HIV: A systematic review. PLoS ONE 2019, 14, e0226347.
  113. Zolopa, A.; Andersen, J.; Powderly, W.; Sanchez, A.; Sanne, I.; Suckow, C.; Hogg, E.; Komarow, L. Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy Trial. PLoS ONE 2009, 4, e5575.
  114. Mussini, C.; Galli, L.; Lepri, A.C.; De Luca, A.; Antinori, A.; Libertone, R.; Angarano, G.; Bonfanti, P.; Castagna, A.; Monforte, A.D.; et al. Incidence, timing, and determinants of bacterial pneumonia among HIV-infected patients: Data from the ICONA Foundation Cohort. J. Acquir. Immune Defic. Syndr. 2013, 63, 339–345.
  115. Birhanu, M.Y.; Habtegiorgis, S.D.; Gietaneh, W.; Alemu, S.; Tsegaye, T.B.; Bekele, G.M.; Abebaw, A.; Dilnessa, T.; Elmneh, H.T.; Amha, H.; et al. Magnitude and associated factors of urinary tract infections among adults living with HIV in Ethiopia. Systematic review and meta-analysis. PLoS ONE 2022, 17, e0264732.
  116. Klasinc, R.; Rieger, A.; Presterl, E.; Wrba, T.; Diab-Elschahawi, M. Epidemiology of Urinary Tract Infections in HIV Positive Patients at a Tertiary Care University Hospital in Central Europe (2011–2016). Infect. Disord. Drug Targets 2018, 18, 199–206.
  117. Gajdács, M.; Ábrók, M.; Lázár, A.; Burián, K. Urinary Tract Infections in Elderly Patients: A 10-Year Study on Their Epidemiology and Antibiotic Resistance Based on the WHO Access, Watch, Reserve (AWaRe) Classification. Antibiotics 2021, 10, 1098.
  118. Pour, A.H.; Salari, S.; Almani, P.G.N. Oropharyngeal candidiasis in HIV/AIDS patients and non-HIV subjects in the Southeast of Iran. Curr. Med. Mycol. 2019, 4, 1–6.
  119. Anwar, K.P.; Malik, A.; Subhan, K.H. Profile of candidiasis in HIV infected patients. Iran. J. Microbiol. 2012, 4, 204–209.
  120. Patil, S.; Majumdar, B.; Sarode, S.C.; Sarode, G.S.; Awan, K.H. Oropharyngeal Candidosis in HIV-Infected Patients—An Update. Front. Microbiol. 2018, 9, 980.
  121. Lopez-Velez, R.; A Perez-Molina, J.; Bellas, C.; Perez-Corral, F.; Villarrubia, J.; Guerrero, A.; Escribano, L.; Baquero, F.; Alvar, J. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am. J. Trop. Med. Hyg. 1998, 58, 436–443.
  122. Kantzanou, M.; Karalexi, M.A.; Theodoridou, K.; Kostares, E.; Kostare, G.; Loka, T.; Vrioni, G.; Tsakris, A. Prevalence of visceral leishmaniasis among people with HIV: A systematic review and meta-analysis. Eur. J. Clin. Microbiol. Infect. Dis. 2023, 42, 1–12.
  123. Obebe, O.O.; Falohun, O.O. Epidemiology of malaria among HIV/AIDS patients in sub-Saharan Africa: A systematic review and meta-analysis of observational studies. Acta Trop. 2020, 215, 105798.
  124. Mirzohreh, S.-T.; Safarpour, H.; Pagheh, A.S.; Bangoura, B.; Barac, A.; Ahmadpour, E. Malaria prevalence in HIV-positive children, pregnant women, and adults: A systematic review and meta-analysis. Parasites Vectors 2022, 15, 324.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Geriatrics & Gerontology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Mohamed H. Ahmed
,
Fatima Ahmed
,
Abu-Bakr Abu-Median
,
Maria Panourgia
,
Henry Owles
,
Bertha Ochieng
,
Hassan Ahamed
,
Jane Wale
,
Benjamin Dietsch
,
Dushyant Mital
View Times: 86
Revisions: 2 times (View History)
Update Date: 17 Oct 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Feedback